Q&A with Avacta CEO, Alastair Smith and Chief Development Officer Neil Bell

Avacta CEO, Alastair Smith and Chief Development Officer Neil Bell, discuss their pre|CISION™ technology and the phase I trial evaluating AVA6000, a pro-drug of Doxorubicin. The go on to discuss the structure of the trial and dose escalation and dose expansion phases and their expectations from the trials.